Iconovo
The answer first
Does Iconovo beat the market?
No, Iconovo has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 29% of Nordic stocks
- Quality82
- Value22
- Trend19
No. 105 of 195 in healthcare
Max for seven days
Follow Iconovo with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Iconovo
Your first answer is free, no account needed.
Do you own Iconovo, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Iconovo and a few more. Free, no card.
Super Stock+44.6%In short
- Iconovo has fallen 30.1% over the past year, including dividends.
- Overall, Iconovo ranks better than 29% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 98.3%. The price is 98.8% below its peak now.
What do analysts think of Iconovo?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 29% of Nordic stocks.
No. 105 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 48 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.05
- Asset turnoverSales divided by everything the company owns0.02
- Return on equityProfit divided by equity−26.1%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 92 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.7
- P/SPrice divided by sales39.8
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 129 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−15.1%
- 6 months−12.1%
- 9 months−9.7%
- 12 months−30.1%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Iconovo
One fund we follow owns Iconovo. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Iconovo
Iconovo is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 12 employees.
Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for interstitial lung disease. The company was incorporated in 2013 and is headquartered in Lund, Sweden.


See the full analysis of Iconovo.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card